YY Inc. (YY) Forms $100.29 Double Top; Scopia Capital Management LP Has Lifted By $3.57 Million Its Horizon Pharma Plc (HZNP) Holding

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Logo

YY Inc. (YY) formed double top with $104.30 target or 4.00% above today’s $100.29 share price. YY Inc. (YY) has $6.34 billion valuation. The stock decreased 4.87% or $5.13 during the last trading session, reaching $100.29. About 1.74 million shares traded. YY Inc. (NASDAQ:YY) has risen 125.46% since May 10, 2017 and is uptrending. It has outperformed by 113.91% the S&P500.

Scopia Capital Management Lp increased Horizon Pharma Plc (HZNP) stake by 1.58% reported in 2017Q4 SEC filing. Scopia Capital Management Lp acquired 254,675 shares as Horizon Pharma Plc (HZNP)’s stock declined 6.58%. The Scopia Capital Management Lp holds 16.37 million shares with $239.01 million value, up from 16.12M last quarter. Horizon Pharma Plc now has $2.28B valuation. The stock decreased 5.60% or $0.82 during the last trading session, reaching $13.81. About 5.56 million shares traded or 195.37% up from the average. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has declined 6.20% since May 10, 2017 and is downtrending. It has underperformed by 17.75% the S&P500.

Among 14 analysts covering YY Inc (NASDAQ:YY), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. YY Inc has $180.0 highest and $45 lowest target. $121.50’s average target is 21.15% above currents $100.29 stock price. YY Inc had 24 analyst reports since August 17, 2015 according to SRatingsIntel. The stock of YY Inc. (NASDAQ:YY) earned “Buy” rating by Jefferies on Wednesday, November 15. HSBC initiated YY Inc. (NASDAQ:YY) on Monday, October 31 with “Buy” rating. Bank of America initiated YY Inc. (NASDAQ:YY) on Monday, November 28 with “Buy” rating. CLSA downgraded YY Inc. (NASDAQ:YY) on Tuesday, March 6 to “Outperform” rating. The firm has “Overweight” rating by Piper Jaffray given on Friday, August 14. The company was maintained on Monday, August 14 by Jefferies. As per Wednesday, August 31, the company rating was initiated by JP Morgan. JP Morgan upgraded the stock to “Overweight” rating in Thursday, November 16 report. The rating was upgraded by J.P. Morgan on Thursday, November 16 to “Buy”. The stock of YY Inc. (NASDAQ:YY) has “Buy” rating given on Thursday, January 18 by Instinet.

Investors sentiment increased to 1.04 in 2017 Q4. Its up 0.04, from 1 in 2017Q3. It increased, as 30 investors sold HZNP shares while 53 reduced holdings. 33 funds opened positions while 53 raised stakes. 128.65 million shares or 2.76% less from 132.29 million shares in 2017Q3 were reported. Schwab Charles Invest Management Incorporated reported 0.01% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Laurion Mngmt LP holds 0% of its portfolio in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 10,600 shares. Raymond James Associates invested in 180,749 shares. Architects has 600 shares for 0% of their portfolio. Rhumbline Advisers reported 181,896 shares stake. Venbio Select Advisor Limited Liability Corporation reported 4.2% stake. James Investment Research Incorporated has invested 0.07% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Parallax Volatility Advisers Limited Partnership invested 0% of its portfolio in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Sterling invested 0.01% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Goldman Sachs Grp Inc Inc has 0% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP). 449,467 were reported by Guggenheim Cap Limited Liability Company. Quantbot Techs LP stated it has 0.1% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Bankshares Of America Corp De has 2.50 million shares. Zeke Cap Advisors Ltd Liability Corporation reported 0.02% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Moreover, Lakeview Cap Partners Ltd Liability Com has 0.28% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP).

YY Inc. (NASDAQ:YY) Ratings Chart

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: